Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. (Q34309626)

1 August 2017

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. (English)

1 reference

1 August 2017

0 references

1 reference

Sheila Breidinger

5

0 references

Ronald Ellis

object named as

Ronald J Ellis

4

0 references

Igor Grant

18

object named as

Igor Grant

1 reference

1 August 2017

2

Scott Letendre

1 reference

1 August 2017

12

Susan Morgello

1 reference

1 August 2017

19

CHARTER Group

1 reference

1 August 2017

15

Florin Vaida

1 reference

1 August 2017

11

Allen McCutchan

1 reference

1 August 2017

9

Christina Marra

1 reference

1 August 2017

8

Benjamin Gelman

1 reference

1 August 2017

3

Brookie M Best

1 reference

1 August 2017

1

David Croteau

1 reference

1 August 2017

10

Gilbert Mbeo

1 reference

1 August 2017

14

Lauren Way

1 reference

1 August 2017

17

Edmund Capparelli

1 reference

1 August 2017

7

Ann Collier

1 reference

1 August 2017

David Clifford

6

1 reference

1 August 2017

David Simpson

13

1 reference

1 August 2017

Susan Ueland

16

1 reference

1 August 2017

language of work or name

English

0 references

publication date

27 September 2010

1 reference

Antimicrobial Agents and Chemotherapy

1 August 2017

1 reference

1 August 2017

54

1 reference

1 August 2017

12

1 reference

1 August 2017

5156-5160

1 reference

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Low atazanavir concentrations in cerebrospinal fluid

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981289

CSF and serum orosomucoid (alpha-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20876368

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid–liquid extraction and HPLC-MS/MS

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20876368

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.00507-10

1 reference

1 August 2017

1 reference

1 August 2017

1 reference